Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor-Reference-Cited by-同舟云学术

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

Published:2014-07-02 Issue:243 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Pegu Amarendra¹,Yang Zhi-yong¹,Boyington Jeffrey C.¹,Wu Lan¹,Ko Sung-Youl¹,Schmidt Stephen D.¹,McKee Krisha¹,Kong Wing-Pui¹,Shi Wei¹,Chen Xuejun¹,Todd John-Paul¹,Letvin Norman L.¹²,Huang Jinghe³,Nason Martha C.⁴,Hoxie James A.⁴,Kwong Peter D.¹,Connors Mark³,Rao Srinivas S.¹,Mascola John R.¹,Nabel Gary J.¹

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 40 Convent Drive, Bethesda, MD 20892, USA.

2. Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02115, USA.

3. HIV-Specific Immunity Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.

4. Biostatistics Research Branch, NIAID, NIH, Bethesda, MD 20892, USA.

Abstract

Neutralizing antibodies to HIV-1 envelope protect more effectively than an antibody to the CD4 cell receptor in rhesus macaques.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference60 articles.

1. HIV vaccine design and the neutralizing antibody problem

2. The Role of Antibodies in HIV Vaccines

3. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection